All Insights
Showing 1921 - 1932 of 7789
Energy and energy transition
Smart power | Preparing for a global supply chain crunch
Welcome to the fifth edition of Smart Power, Osborne Clarke's specialist service for asset managers within the green energy sector
Decarbonisation
European shift to green fleets will revolutionise businesses
What can businesses do to anticipate change in the transport sector and ensure an effective transition?
COP
COP27 | Sharm-el-Sheikh climate pledges pave way for final week of global talks
What happened in the first week of the UN climate change summit and what is on the agenda ahead?
Life Sciences and Healthcare
Commercialising health data: five takeaways from the ICO's Easylife decision
What actions should businesses consider when looking to reuse customer health data?
Knowledge Notes
Knowledge Collection | The ESG agenda, diversity and accent bias, and regulating cryptoassets in the UK
Welcome to this week's Knowledge Collection
Intellectual property
Red Bull dismisses Monster's Red Dawg trade mark appeal in UK High Court
The opposition was upheld on the basis that it would free ride on earlier Red Bull mark
Regulatory and compliance
UK cryptoasset regulation: coming sooner rather than later?
Last minute Treasury amendment to Financial Services Bill may bring all cryptoassets inside the regulatory perimeter
Employment and pensions
UK Employment Law Coffee Break | Accents, employment law reforms and guidance on suspensions
Welcome to our latest Coffee Break in which we look at the latest legal and practical developments impacting employers
Employment and pensions
Q1 2023 UK Pensions Action Plan
The action plan is a summary of changes and proposals in UK pensions law and regulation over the last quarter
Future of work
What does hybrid working mean for your company’s carbon footprint?
There is not yet a consensus about the best way for businesses to measure and address carbon emissions from remote
Life Sciences and Healthcare
EU General Court says risk of similarity between cosmetics and pharmaceuticals in trade mark cases
A blurred line between goods means skincare products may be considered similar across classes 3 and 5
